CHARLOTTE – TG Therapeutics, which has operations in Morrisville, has secured a deal worth up to nearly $650 million to license its multiple sclerosis treatment outside of North America. Sales of the drop hit $16 million in the first full quarter of availability.
In its financial update Tuesday, the company reported quarterly net sales of $16 million in the United States, the first full quarter for sales of the drug called BRIUMVI.
“We are pleased to report our second quarter 2023 results, representing our first full quarter of BRIUMVI sales, which exceeded our expectations,” said CEO Michael Weiss in a statement. “It’s been gratifying to see BRIUMVI adopted by such a broad range of MS centers and providers so early into our launch and we are humbled when we hear positive feedback on patients’ experience with BRIUMVI.
The pharmaceutical company disclosed a deal that grants Neuraxpharm Group an exclusive license to commercialize its treatment in Europe and other countries outside of the U.S., Canada and Mexico.
TG Therapeutics (Nasdaq: TGTX) is based in New York.
